» Articles » PMID: 20725055

Pressor Responses to Antihypertensive Drug Types

Overview
Journal Am J Hypertens
Date 2010 Aug 21
PMID 20725055
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pressor responses to antihypertensive drugs are not addressed in treatment guidelines although they have been described in various clinical situations. We now report the incidence of pressor responses to initiation of monotherapy using four antihypertensive drug types, and the influence of plasma renin activity (PRA) status, among participants in a worksite-based antihypertensive treatment program.

Methods: Systolic blood pressure (SBP) response was evaluated among 945 participants with no prior treatment who were given either a diuretic or calcium-channel blocker (natriuretic antivolume V drugs, n = 537) or a beta-blocker or angiotensin-converting enzyme (ACE) inhibitor (antirenin R drugs n = 408). PRA was categorized by low, middle, and high tertiles (L, M, and H). SBP rise > or =10 mm Hg was considered pressor.

Results: More pressor responses occurred with R than V drugs (11% vs. 5%, P = 0.001). L, M, and H renin tertiles had similar frequencies with V drugs (6, 4, and 6%), but low and middle tertiles given R had greater pressor frequencies (17% P = 0.003 vs. V and 10% P = 0.02 vs. V). Treatment SBP > or =160 mm Hg occurred more frequently with R than V drugs (19% vs. 13%; P = 0.007); moreover, in the lowest renin tertile 35% R vs. 13% V (P = 0.001) had SBP > or =160 mm Hg. Treatment SBP <130 mm Hg was more frequent in V patients in the lowest tertile (18% vs. 5%; P = 0.003), and in R patients in the highest tertile (26% vs. 12%, P = 0.002).

Conclusions: Pressor responses to antihypertensive monotherapy occur sufficiently frequently to be of concern, especially in lower renin patients given a beta-blocker or ACE inhibitor (ACEI).

Citing Articles

Head motion in the UK Biobank imaging subsample: longitudinal stability, associations with psychological and physical health, and risk of incomplete data.

Ward J, Cox S, Quinn T, Lyall L, Strawbridge R, Russell E Brain Commun. 2024; 6(4):fcae220.

PMID: 39015764 PMC: 11249925. DOI: 10.1093/braincomms/fcae220.


Resistant Hypertension: A Real Entity Requiring Special Treatment?.

Taddei S, Bruno R Eur Cardiol. 2018; 11(1):8-11.

PMID: 30310440 PMC: 6159429. DOI: 10.15420/ecr.2016.11.1.


Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.

MacDonald T, Williams B, Webb D, Morant S, Caulfield M, Cruickshank J J Am Heart Assoc. 2017; 6(11).

PMID: 29151036 PMC: 5721778. DOI: 10.1161/JAHA.117.006986.


Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy.

Ghazi L, Drawz P F1000Res. 2017; 6.

PMID: 28413612 PMC: 5365219. DOI: 10.12688/f1000research.9692.1.


Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure.

Bhandari S, Batech M, Shi J, Jacobsen S, Sim J Kidney Res Clin Pract. 2016; 35(4):219-228.

PMID: 27957416 PMC: 5142266. DOI: 10.1016/j.krcp.2016.07.004.